Ipamorelin

Selective growth hormone secretagogue peptide (GHRP). Cleanest GHRP with minimal cortisol and prolactin release. Often stacked with CJC-1295 or mod-GRF.

Overview

Peptide

Selective growth hormone secretagogue peptide (GHRP). Cleanest GHRP with minimal cortisol and prolactin release. Often stacked with CJC-1295 or mod-GRF.

Effects on Markers

Increases GH and IGF-1 levels, does not significantly raise cortisol or prolactin (unlike GHRP-2/6), minimal impact on appetite (unlike GHRP-6 and MK-677), may mildly elevate fasting glucose with prolonged use

Compound Guide

Structure: Pentapeptide GH secretagogue. Selective for GH release with minimal stimulation of cortisol, prolactin, or appetite pathways.

Dosage:

  • Standard: 200-300mcg 2-3x/day (before meals or before bed)
  • Combined with mod-GRF: 100mcg Ipamorelin + 100mcg mod-GRF per injection, 2-3x/day
  • Anti-aging: 200mcg before bed

Administration:

  • SubQ injection, 27-30g insulin syringe
  • Best on empty stomach (30+ min before food)
  • Pre-bed injection captures natural GH pulse during sleep

Key Notes:

  • Cleanest GH secretagogue — no significant cortisol or prolactin increase (unlike GHRP-2 and GHRP-6)
  • No significant hunger increase (unlike GHRP-6 and MK-677)
  • Synergistic with GHRH analogs (mod-GRF, CJC-1295) — GHRH + GHRP together amplify GH release
  • Multiple daily injections needed due to short half-life — less convenient than CJC-1295 DAC or MK-677
  • Monitor: IGF-1, fasting glucose
  • Very well tolerated — one of the best entry-level peptides for GH optimisation
  • Reconstitute with bacteriostatic water, store refrigerated

What to expect from your IGF-1 and glucose on this stack, with head-to-head data against MK-677: How to read your labs on CJC-1295 and ipamorelin.

Usage History

Pairs With

How Ipamorelin behaves when it is run alongside other compounds.

Commonly stacked with

Used to offset

Stacks the risk

Frequently Asked Questions

Quick Reference

Category

Peptide

Half-Life

~2 hours

Detection Time

N/A

Usage Summary